Shots:
- The CHMP has granted positive opinion to 1L Loqtorzi with cisplatin & gemcitabine for recurrent, metastatic NPC as well as with cisplatin & paclitaxel for unresectable advanced, recurrent or metastatic ESCC; valid across the EU plus Iceland & Norway
- The opinions for NPC & ESCC were supported by P-III (JUPITER-02 & JUPITER-06) trials, respectively; JUPITER-02 results were highlighted at ASCO 2021 & published in Nature Medicine & JAMA, with JUPITER-06 results featured at ESMO 2021 & published in Cancer Cell & Journal of Clinical Oncology
- Toripalimab, an anti-PD-1 mAb, works by blocking PD-1 interactions with PD-L1 & PD-L2 ligands to improve endocytosis function
Ref: Global News Wire | Image: Junshi Biosciences | Press Release
Related News:- Astellas Reports the CHMP’s Positive Opinion of Zolbetuximab to Treat Gastric and Gastroesophageal Junction Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
